Aptevo Therapeutics Inc (NASDAQ:APVO) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1-year consensus price target of $10.50 for the company and are forecasting that the company will post ($0.65) earnings per share for the current quarter, according to Zacks. Zacks has also given Aptevo Therapeutics an industry rank of 158 out of 255 based on the ratings given to related companies.
A number of equities research analysts have weighed in on the company. ValuEngine upgraded Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. Piper Jaffray Companies raised their price target on Aptevo Therapeutics from $6.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, May 10th. Finally, Roth Capital assumed coverage on Aptevo Therapeutics in a research report on Wednesday, April 11th. They set a “buy” rating and a $12.00 price target on the stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC raised its position in Aptevo Therapeutics by 215.4% during the first quarter. Citadel Advisors LLC now owns 39,653 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 27,079 shares in the last quarter. Spark Investment Management LLC raised its position in Aptevo Therapeutics by 82.8% during the first quarter. Spark Investment Management LLC now owns 129,400 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 58,600 shares in the last quarter. Virtu Financial LLC purchased a new stake in Aptevo Therapeutics during the fourth quarter valued at about $690,000. Park West Asset Management LLC purchased a new stake in Aptevo Therapeutics during the first quarter valued at about $604,000. Finally, Alambic Investment Management L.P. purchased a new stake in Aptevo Therapeutics during the first quarter valued at about $646,000. Institutional investors and hedge funds own 34.16% of the company’s stock.
NASDAQ:APVO traded up $0.13 during trading hours on Friday, hitting $5.09. 52,900 shares of the company’s stock traded hands, compared to its average volume of 180,702. The firm has a market capitalization of $112.71 million, a price-to-earnings ratio of -3.33 and a beta of 0.74. Aptevo Therapeutics has a 52 week low of $1.15 and a 52 week high of $6.35. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.39 and a current ratio of 4.47.
Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.07). The company had revenue of $4.07 million during the quarter, compared to the consensus estimate of $3.37 million. equities analysts forecast that Aptevo Therapeutics will post -2.63 earnings per share for the current fiscal year.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.